8-K: Onconetix Receives Additional Nasdaq Delisting Notice and Secures Short-Term Financing

Onconetix, Inc. faces further Nasdaq delisting concerns due to delayed financial filings while securing a $294,117.65 promissory note to address immediate financial needs.

Summary

• Onconetix, Inc. received a deficiency notice from Nasdaq on May 20, 2025, for failing to file its Q1 2025 report (Form 10-Q) on time.
• This is in addition to a previous notice for failing to file its 2024 annual report (Form 10-K).
• The company is also at risk of delisting due to its stock price falling below the minimum bid price requirement.
• Onconetix has requested a hearing with the Nasdaq Hearings Panel, scheduled for May 27, 2025, to appeal the potential delisting.
• To address immediate financial needs, Onconetix issued a promissory note to Keystone Capital Partners, LLC for $294,117.65, with an original issue discount of $44,117.65, resulting in net proceeds of $250,000.
• The note is due on February 16, 2026, or earlier upon receipt of proceeds from the company's Equity Line of Credit.
• The note is subordinate to Onconetix's existing debt obligations to Veru Inc.
• Late payments on the note will incur a 15% per annum late charge.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notices, delayed financial filings, and the need for short-term financing with unfavorable terms. While the company is taking steps to address these issues, the overall outlook is uncertain.

Positives

• Onconetix secured short-term financing through a promissory note, providing immediate capital.
• The company is actively appealing the Nasdaq delisting notices and working to regain compliance.
• The hearing with the Nasdaq Hearings Panel provides an opportunity to present its case for continued listing.

Negatives

• Onconetix is facing multiple Nasdaq delisting notices due to delayed financial filings and low stock price.
• The promissory note is subordinate to existing debt, increasing financial risk.
• The company is incurring a significant original issue discount on the promissory note, effectively raising the cost of capital.
• Late payments on the note will incur a high late charge of 15% per annum.

Risks

• There is no guarantee that the Nasdaq Hearings Panel will grant Onconetix's request for continued listing.
• Failure to file the overdue financial reports could lead to delisting from Nasdaq.
• The company's ability to repay the promissory note depends on receiving proceeds from its Equity Line of Credit or other financing.
• The subordinate nature of the note increases the risk for the investor.
• Continued non-compliance with Nasdaq listing rules could negatively impact investor confidence and the company's ability to raise capital.

Future Outlook

The company intends to file the Form 10-K and 10-Q as promptly as possible in order to regain compliance with the Nasdaq Listing Rule 5250(c)(1).

Management Comments

• The company is working diligently to finalize and file the 10-K and the 10-Q as soon as practicable on or prior to the hearing date.

Industry Context

Biotechnology companies, especially those in the commercial stage, often face challenges in maintaining Nasdaq listing compliance due to financial constraints and regulatory hurdles. Delayed financial filings and low stock prices are common issues that can lead to delisting notices. Securing short-term financing is a typical strategy to address immediate financial needs while pursuing long-term growth and compliance.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges with Nasdaq compliance, particularly regarding minimum bid price and timely financial reporting.
• Companies like Veru Inc., to which Onconetix's debt is subordinate, represent a more established player in the men's health space.
• The terms of the promissory note, including the original issue discount and late charge, are relatively standard for short-term financing in high-risk situations.
• The reliance on an Equity Line of Credit for repayment is a common strategy for companies seeking to raise capital, but it also introduces uncertainty regarding the timing and availability of funds.

Stakeholder Impact

• Shareholders face the risk of delisting, which could negatively impact the stock price.
• Employees may experience uncertainty due to the company's financial challenges.
• The company's ability to invest in research and development may be limited due to financial constraints.
• Creditors face increased risk due to the company's financial difficulties.

Next Steps

• Onconetix needs to file its overdue 10-K and 10-Q reports as soon as possible.
• The company must prepare for the hearing with the Nasdaq Hearings Panel on May 27, 2025.
• Onconetix needs to secure funding through its Equity Line of Credit or other means to repay the promissory note.
• The company must monitor its stock price to ensure compliance with the minimum bid price rule.

Key Dates

Keywords

Onconetix, Nasdaq, Delisting, Promissory Note, Keystone Capital Partners, Financial Filing, Deficiency Notice, Equity Line of Credit, Minimum Bid Price, Debt